Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Table 2

Medical history of AIG-IV recipients and nonrecipients, Scotland, UK, 2009–2010*

Variable AIG-IV nonrecipient AIG-IV recipient p value
Presentation and clinical history
Days from exposure to symptom onset, median (IQR) 1 (0.0–4.0), n = 18 2 (1.0–4.5), n = 12 0.19
Days from symptom onset to hospitalization, median (IQR) 2 (1.0–3.0), n = 25 2.0 (1.0–5.0), n = 14 0.55
Age, y, mean ± SE 34.2 ± 1.5, n = 28 37.5 ± 1.6, n = 15 0.18
Male sex 60.7 (17/28) 73.3 (11/15) 0.41
Smoker 94.4 (17/18) 81.8 (9/11) 0.54
Alcohol user 33.3 (5/15) 58.3 (7/12) 0.19
Hepatitis C infection
 60 (9/15)
 77.8 (7/9)
 0.66
Drug injection route and site
Intravenous 50 (14/18) 40 (6/15) 0.53
Intramuscular 21.4 (6/28) 46.7 (7/15) 0.16
Arm 39.3 (11/28) 26.7 (4/15) 0.41
Groin 25 (7/28) 26.7 (4/15) 1.00
Buttock 7.1 (2/28) 26.7 (4/15) 0.16
Leg
 10.7(3/28)
 6.7 (1/15)
 1.00
Presenting complaints
Local† 67.9 (19/28) 53.3 (8/15) 0.54
General‡ 17.9 (5/28) 20.0 (3/15)
Both% 14.3 (4/28) 26.7 (4/15)

*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate number of patients for whom data were available. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
†Skin lesion, limb swelling, or limb pain.
‡Fever, diaphoresis, confusion, seizures, lethargy, or malaise.

Main Article

1These authors contributed equally to this article.

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external